Medicine
Vyvanse 50 mg chewable tablet
Vyvanse 50 mg chewable tablet is a prescription medicine containing Lisdexamfetamine for oral use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature, 20°C to 25°C (68°F to 77°F). Excursions permitted…
Key facts
- Active ingredient (INN)
- Lisdexamfetamine
- Brand
- Vyvanse
- Strength
- 50 mg
- Dosage form
- Chewable tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at room temperature, 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CII
- ATC code
- N06BA12 Lisdexamfetamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 January 2017
- Identifiers
- RxCUI 854830, 854832, 854834 +7DailyMed set ID 704e4378-ca83-445c-8b45-3cfa51c1ecadNDC 59417-119Application NDA208510
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, chewable in 1 bottle | 59417-119-01 | Takeda Pharmaceuticals | 28 January 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 February 2007 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lisdexamfetamine 50 mg chewable tablet.
Other strengths and forms of Lisdexamfetamine
Clinical summary
Lisdexamfetamine is a central nervous system stimulant indicated for the treatment of attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older, among other approved uses. MedsAcross supplies Lisdexamfetamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LisdexamfetamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vyvanse prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Vyvanse 50 mg chewable tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.